Research is an important step in combating the health burden caused by sexually transmitted infections (STIs). In 2018, the Centers for Disease Control and prevention (CDC) report 1 in 5 people in the US have an STI, with a total of nearly 68 million cases1. 2021 surveillance data highlights the ongoing threat of STIs to the US, noting over 700,000 cases of gonorrhea, which is a 28% increase in the past 4 years2. Antibiotic resistance (AMR) in these organisms is having a huge impact on health economy. AMR is considered a global threat, with guidelines across US, EU, UK and AU now supporting the use of AMR assays to detect antibiotic resistant STIs.
At SpeeDx, innovative technology is our backbone. The PlexZyme® and universal probes are integral components of our patented qPCR techniques, providing clean, specific amplification with vast multiplexing capabilities.
Leaders in STI innovation, SpeeDx work closely with Key Opinion Leaders (KOLs) around the globe to address specific STI concerns. We apply our proprietary technology to help researchers further understand and combat the ongoing issue of Antimicrobial Resistance (AMR) within STI organisms. Pioneers in STI innovation, we commercialised our first product in 2016, which simultaneously detects Mycoplasma genitalium (MG) and multiple antibiotic resistance markers.
SpeeDx continue to develop STI assays addressing concerns with AMR and other unmet needs. SpeeDx innovative technology is versatile, with further research use only assays available across a number of disciplines.
SpeeDx understands the right workflow will make your work flow right.
Streamlined to minimize hands-on time
Flexible for easy adjustment to sample throughput, whilst maintaining productivity
Scalable to grow with your needs
SpeeDx helps keep your research costs down